Fig. 8: Reducing mAngptl7 levels in mice lowers IOP.
From: ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma
a IOP was significantly lowered in Angptl7 KO compared to Het and WT mice (mean ± SEM; **** = P < 1 × 10–4). b Comparison of conventional outflow facility (C) between KO and WT mice. In KO mice (n = 7), C was increased compared to WT mice (n = 4, P = 0.16, unpaired Student’s t test). Data are presented as mean ± SEM. c Intravitreal injection with 15 µg of Angptl7-siRNA significantly lowered IOP in two of six siRNAs tested (n = 6–8/group) compared to the PBS (n = 6) and Naïve (no injection, n = 5) groups and remained lowered throughout the end of the study. siRNAs 3 and 5 lowered IOP between 2 and 4 mmHg starting at week 2 compared to PBS-treated mice. * = P < 0.05, ** = P < 0.01, *** = P < 1 × 10−3, **** = P < 1 × 10−4 statistical difference between the mean IOP for siRNA #5 and PBS-treatment.# = P < 0.05,## = P < 0.01, ### = P < 1 × 10−3, #### = P < 1 × 10−4 statistical difference between the mean IOP for siRNA #3 and PBS-treatment. d qPCR results from micro-dissected limbal ring showed the highest level of knockdown (>50%) of Angptl7 mRNA with siRNAs #3 and #5 compared to PBS-treated mice, which is highly consistent with the IOP lowering observed in mice injected with these two siRNAs (b). Data are presented as mean and error bars represent SEM.
